S0947000
Somatropin
European Pharmacopoeia (EP) Reference Standard
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
El producto S0947000 no se vende actualmente en su país. Póngase en contacto con el Servicio técnico
Productos recomendados
grado
pharmaceutical primary standard
familia API
somatropin
fabricante / nombre comercial
EDQM
aplicaciones
pharmaceutical (small molecule)
Formato
neat
temp. de almacenamiento
−20°C
¿Está buscando productos similares? Visita Guía de comparación de productos
Descripción general
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Aplicación
Somatropin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Envase
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Otras notas
Sales restrictions may apply.
Producto relacionado
Referencia del producto
Descripción
Precios
Código de clase de almacenamiento
11 - Combustible Solids
Clase de riesgo para el agua (WGK)
WGK 3
Punto de inflamabilidad (°F)
Not applicable
Punto de inflamabilidad (°C)
Not applicable
Elija entre una de las versiones más recientes:
Certificados de análisis (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.
Si necesita más asistencia, póngase en contacto con Atención al cliente
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
M Kuzma et al.
Bratislavske lekarske listy, 114(12), 689-695 (2013-12-18)
Growth hormone deficiency (GHD) is associated with reduced bone mineral content and increased risk of osteoporotic fractures. Reduced peak bone mass might explain the low bone mineral density (BMD) among patients with childhood onset GHD (CO-GHD) whilst the cause of
O V Bol'shova et al.
Likars'ka sprava, (5)(5), 70-75 (2014-03-13)
The objective was to study blood Zinc levels and hair Zinc content in three subsets of 40 naive patients (29 boys) with childhood onset GH deficiency (isolated total GHD, partial GHD, syndrome biological inactive GH). Our data showed that GHD
Ralf Nass et al.
The Journal of clinical endocrinology and metabolism, 99(2), 602-608 (2013-11-29)
Acyl-ghrelin is thought to have both orexigenic effects and to stimulate GH release. A possible cause of the anorexia of aging is an age-dependent decrease in circulating acyl-ghrelin levels. The purpose of the study was to compare acyl-ghrelin and GH
Bilal Battal et al.
The neuroradiology journal, 27(1), 55-62 (2014-02-28)
Brain herniations into dural venous sinuses (DVS) are rare findings recently described and their etiology and clinical significance are controversial. We describe five patients with brain herniations into the DVS or calvarium identified on MRI, and discuss their imaging findings
A Thankamony et al.
The Journal of clinical endocrinology and metabolism, 99(2), 639-647 (2014-01-16)
Data on the metabolic effects of GH derived from studies using GH suppression by pharmacological agents may not reflect selective actions. The purpose of this study was to evaluate the effects of GH antagonism on glucose and lipid metabolism using
Filtros activos
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico
